Kayyem Jon Faiz 4

What Happened
Kayyem Jon Faiz, a director of Inhibrx Biosciences, was granted derivative securities covering 15,000 shares (transaction code A — award/grant) on June 3, 2026. The reported acquisition price is $0.00 (no cash paid at grant), and the filing lists this as a derivative award rather than an immediate share purchase.

Key Details

• Transaction date: 2026-06-03; Form 4 filed: 2026-06-04 (timely filing).
• Security: Derivative award covering 15,000 shares; reported price $0.00.
• Ownership after transaction: Not specified in the provided summary — see the full Form 4 for post-transaction holdings.
• Footnote: The award "will be fully exercisable on June 3, 2027, subject to the reporting person's continued service through such date" (F1).
• Transaction type: A = Award/Grant (not a purchase or sale).

Context
This is a time-based derivative award (likely stock options or similar) that does not result in immediate owned common stock; it vests/ becomes exercisable one year later if the director remains in service. Such director awards are common as compensation and do not by themselves indicate buying or selling sentiment. For details on exercise price, vesting schedule beyond the one-year full exercisability, or post-grant holdings, consult the full Form 4 filing.